Organic acids as agents to dissolve calcium minerals in pathological calcification and uses thereof

Abstract

In an embodiment of the present disclosure, there is provided a composition for dissolving calcium oxalate crystals thereby inhibiting/preventing further growth of crystals. In some embodiments, such a composition comprises at least one stereoisomer of hydroxycitrate, a derivative of the organic acid citrate. Such a method comprises administering to the subject an effective amount of the aforementioned composition. In another embodiment, the present disclosure pertains to a method of treating kidney stone disorder. Such a method comprises administering to a subject in need thereof a therapeutically effective amount of the aforementioned composition. In yet another embodiment, the present disclosure relates to a method of treating calcium oxalate stone disease. In an embodiment, the method comprises administering to a subject in need thereof a therapeutically effective amount of the aforementioned composition.

What is claimed is: 
     
         1 . A composition for dissolving at least one of a calcium oxalate crystal or calcium phosphate crystal, said composition consisting of:
 (2S,3S) hydroxycitrate, wherein the (2S,3S) hydroxycitrate is present at a concentration capable of binding to at least one of the calcium oxalate crystal or the calcium phosphate crystal to dissolve the crystal; and   at least one pharmaceutically acceptable carrier, wherein the at least one pharmaceutically acceptable carrier comprises at least one excipient.   
     
     
         2 . The composition of  claim 1 , wherein at least one of the calcium oxalate crystal or the calcium phosphate crystal comprises a kidney stone. 
     
     
         3 . The composition of  claim 1 , wherein the composition is in a form suitable for oral administration to a subject in need thereof. 
     
     
         4 . The composition of  claim 3 , wherein the subject in need thereof has a kidney stone disorder. 
     
     
         5 . The composition of  claim 4 , wherein the kidney stone disorder is caused by hypercalciuria, a family history of kidney stones, gout disease, hyperparathyroidism, renal tubular acidosis, hypocitraturia, or hyperoxaluria. 
     
     
         6 . The composition of  claim 4 , wherein the composition is administered simultaneously with a therapeutically effective amount of a diuretic. 
     
     
         7 . The composition of  claim 1 , wherein the (2S,3S) hydroxycitrate is combined with the at least one excipient. 
     
     
         8 . A method of controlling the growth of at least one of a calcium oxalate crystal or calcium phosphate crystal in a subject in need thereof, said method comprising:
 a step of administering to the subject an effective amount of a composition, said composition consisting of:   (2S,3S) hydroxycitrate, wherein the (2S,3S) hydroxycitrate is administered at a concentration capable of binding to at least one of the calcium oxalate crystal or the calcium phosphate crystal to dissolve the crystal; and   at least one pharmaceutically acceptable carrier, wherein the at least one pharmaceutically acceptable carrier comprises at least one excipient.   
     
     
         9 . The method of  claim 8 , wherein the subject has a renal calcification disorder. 
     
     
         10 . The method of  claim 8 , wherein the subject has a biomineralization induced disease. 
     
     
         11 . The method of  claim 8 , further comprising administering the composition post lithotripsy. 
     
     
         12 . The method of  claim 8 , wherein the (2S,3S) hydroxycitrate is combined with the at least one excipient. 
     
     
         13 . The method of  claim 8 , wherein the (2S,3S) hydroxycitrate is administered at a concentration capable of binding to a crystal surface of at least one of the calcium oxalate crystal or the calcium phosphate crystal to dissolve the crystal. 
     
     
         14 . The method of  claim 8 , wherein the subject has a kidney stone disorder, and wherein the method is utilized to treat the kidney stone disorder. 
     
     
         15 . The method of  claim 14 , wherein the kidney stone disorder is caused by calcium oxalate crystal formation. 
     
     
         16 . The method of  claim 14 , wherein the kidney stone disorder is calcium oxalate stone disease. 
     
     
         17 . The method of  claim 14 , wherein the kidney stone disorder is caused by calcium phosphate crystal formation. 
     
     
         18 . The method of  claim 14 , wherein the subject has an existing kidney stone.